News & Updates

Preventing exacerbations remains a primary goal in asthma management. In an interview with MIMS Doctor, Dr Herbert Kwok of the Department of Medicine, the University of Hong Kong, discussed challenges in achieving this goal, particularly in patients with difficult-to-treat type 2 (T2)–low disease, and shared real-world cases from his practice. He also offered insights into the role of airway hyperresponsiveness (AHR) in asthma and explained how blocking thymic stromal lymphopoietin (TSLP) with tezepelumab can prevent exacerbations and improve AHR across a broad range of severe asthma patients.